- Immunex sells Leukine to Schering AG
- Enzon gets rights to Elan's Abelcet for $370mm
- Isotechnika, Roche sign $215mm Canadian drug development deal
- Roche licenses Stressgen's HspE7 anti-HPV therapy
- GSK, Exelixis co-develop, -promote therapeutics; terminated
- Genta, Aventis sign $480mm antisense deal; ended
- Pfizer, Neurocrine end agreement for indiplon
- Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.